Owners, management and financials
CVR: 13246149
Previous names: A/S PSE NR. 3369, FERROSAN FINE CHEMICALS A/S, FEF CHEMICALS A/S
DKK 1,041,584,000
Revenue
Net result: DKK 113,891,000
NOVO NORDISK A/S (100%)
CVR · view owners
Ulla Grove Krogsgaard Thomsen
Board: Mette Sofie Mørck Jarl (chair) and 5 members
CVR · view management
Active
Founded 1 July 1989
CVR · view overview
493 employees
CVR · 2026
Director registered: Ulla Grove Krogsgaard Thomsen
CVR · 01/04/2021
View the full event history
Novo Nordisk Pharmatech A/S is a Danish company of the type Aktieselskab based in Køge, founded in 1989. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named FEF CHEMICALS A/S and FERROSAN FINE CHEMICALS A/S. The management consists of Ulla Grove Krogsgaard Thomsen. The board consists of Mette Sofie Mørck Jarl (chair), Christian Brøgger Stolberg, Jacob Sten Petersen and Joachim Juel Hagemeister. The company is owned by NOVO NORDISK A/S. The company has 493 employees (2026). In 2025, the company reported revenue of DKK 1,041,584,000 and a net result of DKK 113,891,000 compared with DKK 60,619,000 the year before. Equity in the 2025 report amounted to DKK 2,441,318,000.
Source: annual report 2025, Danish Business Authority
Novo Nordisk Pharmatech A/S demonstrates strong financial health with a notable upward trajectory in revenue and profit over recent years. Revenue increased from 598 million DKK in 2022 to over 1 billion DKK in 2025, while profit surged from 39 million DKK in 2022 to nearly 114 million DKK in 2025, indicating robust growth. The company's equity has also significantly improved, rising from 689 million DKK in 2022 to 2.44 billion DKK in 2025, reflecting a solid financial foundation. Key strengths include its increasing profit margins and strong equity position, although the absence of a calculated CDS score may raise some concerns regarding its debt profile. Positioned within the pharmaceutical manufacturing industry, the company is likely benefiting from growing demand for its products.
AI-generated summary · Generated 10/04/2026
Selskabets formål er at drive handel og industri
Source: annual reports filed with the Danish Business Authority.
| Period | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 1 mia. | 113.9 mio. | 3.1 mia. | 2.4 mia. | 529 | |
| 202401/01/2024 – 31/12/2024 | 956 mio. | 60.6 mio. | 2 mia. | 1.3 mia. | 461 | |
| 202301/01/2023 – 31/12/2023 | 880.4 mio. | 77.2 mio. | 1.3 mia. | 766.9 mio. | 336 | |
| 202201/01/2022 – 31/12/2022 | 598.3 mio. | 39.3 mio. | 966.9 mio. | 689.6 mio. | 244 | |
| 202101/01/2021 – 31/12/2021 | 619.1 mio. | 113.7 mio. | 639.9 mio. | 520.2 mio. | 212 | |
| 202001/01/2020 – 31/12/2020 | 667.7 mio. | 114.9 mio. | 745.5 mio. | 606.4 mio. | 197 | |
| 201901/01/2019 – 31/12/2019 | 621 mio. | 97.3 mio. | 809.4 mio. | 691.5 mio. | 184 | |
| 201801/01/2018 – 31/12/2018 | 690.7 mio. | 105.3 mio. | 760.8 mio. | 614.2 mio. | 170 | |
| 201701/01/2017 – 31/12/2017 | 622.4 mio. | 103.7 mio. | 676.4 mio. | 529 mio. | 163 | |
| 201601/01/2016 – 31/12/2016 | 669.1 mio. | 87.4 mio. | 653.8 mio. | 468.3 mio. | 158 | |
| 201501/01/2015 – 31/12/2015 | 505.2 mio. | 92.1 mio. | 618.6 mio. | 400.9 mio. | 150 | |
| 201401/01/2014 – 31/12/2014 | 495.2 mio. | 55.3 mio. | 452.1 mio. | 336.8 mio. | 150 | |
| 201301/01/2013 – 31/12/2013 | 498 mio. | 46.7 mio. | 427.8 mio. | 304.5 mio. | 141 |
Compared to 129 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
9 properties
Upgrade to Pro to see addresses, building data and ownership details
Property report (PDF)
The entire property portfolio in one report: areas, usage, energy labels, flood exposure, planning zone and local plans.
See an example report (PDF)Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Novo Nordisk Pharmatech A/S is 13246149.
Novo Nordisk Pharmatech A/S is owned by NOVO NORDISK A/S.
The management of Novo Nordisk Pharmatech A/S consists of Ulla Grove Krogsgaard Thomsen.
The board of Novo Nordisk Pharmatech A/S consists of Mette Sofie Mørck Jarl, Christian Brøgger Stolberg and Jacob Sten Petersen, with Mette Sofie Mørck Jarl as chair.
In 2025, Novo Nordisk Pharmatech A/S reported revenue of DKK 1,041,584,000.
Novo Nordisk Pharmatech A/S had 493 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Novo Nordisk Pharmatech A/S has published its annual report for 2025. Revenue came to DKK 1,041,584,000, and the net result was DKK 113,891,000.
Contact info changed: new phone: 56671000 (March 30, 2026).
As of March 17, 2026, Mette Sofie Mørck Jarl has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 17, 2026, Jean Fabian Jeldorf has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 16, 2026, Mette Sofie Mørck Jarl has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 30, 2025, Hazal Polat has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2024. Revenue came to DKK 956,033,000, and the net result was DKK 60,619,000.
As of March 12, 2025, Karina Sinding has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 12, 2025, Mette Sofie Mørck Jarl has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 12, 2025, Julie Aunbirk has left the board of directors of Novo Nordisk Pharmatech A/S.
As of November 15, 2024, Christian Brøgger Stolberg has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of November 14, 2024, Zohra Mansour has left the board of directors of Novo Nordisk Pharmatech A/S.
As of November 14, 2024, Christian Brøgger Stolberg has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2023. Revenue came to DKK 880,400,000, and the net result was DKK 77,247,000.
As of March 11, 2024, Hazal Polat has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 11, 2024, Christian Brøgger Stolberg has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 11, 2024, Knud Edgar Striib Nielsen has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2022. Revenue came to DKK 598,265,000, and the net result was DKK 39,307,000.
As of March 15, 2023, Julie Aunbirk has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 15, 2023, Søren Thor Jensen has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2021. Revenue came to DKK 619,083,000, and the net result was DKK 113,748,000.
As of June 1, 2021, Jacob Sten Petersen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of April 1, 2021, Ulla Grove Krogsgaard Thomsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of April 1, 2021, Ulla Grove Krogsgaard Thomsen is registered as adm. dir. of Novo Nordisk Pharmatech A/S.
As of April 1, 2021, Bo Højriis Frandsen has stepped down as adm. dir. of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2020. Revenue came to DKK 667,729,000, and the net result was DKK 114,915,000.
As of March 1, 2021, Bo Højriis Frandsen is registered as adm. dir. of Novo Nordisk Pharmatech A/S.
As of February 28, 2021, Rasmus Hother le Fevre has stepped down as adm. dir. of Novo Nordisk Pharmatech A/S.
As of February 24, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Pharmatech A/S.
As of February 24, 2021, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Novo Nordisk Pharmatech A/S.
As of October 1, 2020, Tue Micheelsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 15, 2020, Jean Fabian Jeldorf has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 15, 2020, Henrik Ehlers Wulff has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 14, 2020, Jean Fabian Jeldorf has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2019. Revenue came to DKK 620,992,000, and the net result was DKK 97,298,000.
As of March 18, 2020, Knud Edgar Striib Nielsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 18, 2020, Jean Fabian Jeldorf has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 18, 2020, Zohra Mansour has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 18, 2020, Claus Steensen Sølje has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 18, 2020, Henrik Kaj Dvinge has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 18, 2020, Vesna Maria Schneider has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2018. Revenue came to DKK 690,700,000, and the net result was DKK 105,268,000.
As of January 24, 2019, Ulla Grove Krogsgaard Thomsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of January 24, 2019, Michael Fugl Hallgren has left the board of directors of Novo Nordisk Pharmatech A/S.
As of November 1, 2018, Søren Thor Jensen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of November 1, 2018, Ole Falvig Ramsby has left the board of directors of Novo Nordisk Pharmatech A/S.
As of June 30, 2018, Lars Sørensen has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2017. Revenue came to DKK 622,436,000, and the net result was DKK 103,665,000.
Novo Nordisk Pharmatech A/S has published its annual report for 2016. Revenue came to DKK 669,077,000, and the net result was DKK 87,367,000.
As of January 27, 2017, Claus Steensen Sølje has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of October 31, 2016, Peter Helt Jacobsen Haahr has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2015. Revenue came to DKK 505,233,000, and the net result was DKK 92,104,000.
As of May 13, 2016, Joachim Juel Hagemeister has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 13, 2016, Vesna Maria Schneider has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 13, 2016, Lars Sørensen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 13, 2016, Erik Frederik Johannes Mortensen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 13, 2016, Camilla Mølbak Sønderris has left the board of directors of Novo Nordisk Pharmatech A/S.
As of September 24, 2015, Lene Due Svensson has left the board of directors of Novo Nordisk Pharmatech A/S.
On August 28, 2015, the company changed its name from FEF CHEMICALS A/S to Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2014. Revenue came to DKK 495,202,000, and the net result was DKK 55,343,000.
As of January 23, 2015, Michael Fugl Hallgren has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of January 23, 2015, Henrik Ehlers Wulff has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of January 23, 2015, Per Toft Valstorp has left the board of directors of Novo Nordisk Pharmatech A/S.
As of January 23, 2015, Jan Hoff has left the board of directors of Novo Nordisk Pharmatech A/S.
Novo Nordisk Pharmatech A/S has published its annual report for 2013. Revenue came to DKK 497,979,000, and the net result was DKK 46,703,000.
Novo Nordisk Pharmatech A/S has published its annual report for 2012.
As of September 3, 2012, Peter Helt Jacobsen Haahr has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of September 1, 2012, Rasmus Hother le Fevre is registered as adm. dir. of Novo Nordisk Pharmatech A/S.
As of September 1, 2012, Søren Damtoft has stepped down as director of Novo Nordisk Pharmatech A/S.
As of March 20, 2012, Lene Due Svensson has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 20, 2012, Henrik Kaj Dvinge has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 20, 2012, Camilla Mølbak Sønderris has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 20, 2012, Poul Erik Noer Søderdahl has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 20, 2012, Camilla Mølbak Sønderris has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 20, 2012, Lars Bjørk has left the board of directors of Novo Nordisk Pharmatech A/S.
As of February 10, 2012, Jan Hoff has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of February 10, 2012, Henrik Ehlers Wulff has left the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 2011, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Novo Nordisk Pharmatech A/S.
As of July 1, 2011, A/S PSE NR. 4820 has stepped down as auditor of Novo Nordisk Pharmatech A/S.
As of February 9, 2011, Susanne Møberg Hundsbæk-Pedersen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 5, 2009, Henrik Ehlers Wulff has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 5, 2009, Jesper Giede Bøving has left the board of directors of Novo Nordisk Pharmatech A/S.
As of February 9, 2009, Susanne Møberg Hundsbæk-Pedersen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of February 9, 2009, Jesper Kløve has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 31, 2008, Poul Erik Noer Søderdahl has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 31, 2008, Camilla Mølbak Sønderris has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 31, 2008, Lars Bjørk has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 31, 2008, Jesper Frank Morthensen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 31, 2008, Eva Kjer Hansen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 31, 2008, Louise Thiel has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 23, 2007, Jesper Kløve has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 23, 2007, Kim Tosti Nielsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of April 16, 2004, Jesper Frank Morthensen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of April 16, 2004, Louise Thiel has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of April 16, 2004, Bente Margrethe Skov Schultz has left the board of directors of Novo Nordisk Pharmatech A/S.
As of January 23, 2004, Kim Tosti Nielsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of September 1, 2003, Søren Damtoft is registered as director of Novo Nordisk Pharmatech A/S.
As of September 1, 2003, Preben Engelund Poulsen has stepped down as director of Novo Nordisk Pharmatech A/S.
As of April 4, 2001, Per Andersen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 29, 2000, Per Toft Valstorp has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 29, 2000, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 29, 2000, Jesper Giede Bøving has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of May 29, 2000, Bjarne Mølgaard Knudsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 29, 2000, Jens Hartvig Jørgensen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 1, 2000, Bente Margrethe Skov Schultz has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 1, 2000, Erik Frederik Johannes Mortensen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 1, 2000, Eva Kjer Hansen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of March 1, 2000, Hans Georg Boye Nielsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 1, 2000, Poul Lasse Jespersen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 1, 2000, Kim Antero Bjørnholt has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 1, 2000, Jesper Frank Morthensen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of March 1, 2000, Bente Margrethe Skov Schultz has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 21, 1999, Steen Skjold-Jørgensen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of August 21, 1997, Steen Skjold-Jørgensen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of August 21, 1997, Ole Regnar Hansen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 20, 1997, Bjarne Mølgaard Knudsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of September 1, 1996, Poul Lasse Jespersen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of September 1, 1996, Poul Lasse Jespersen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of August 31, 1996, Birgit Mindegaard has left the board of directors of Novo Nordisk Pharmatech A/S.
As of August 31, 1996, Poul Lasse Jespersen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of November 20, 1995, Sonnich Jacob Fryland has left the board of directors of Novo Nordisk Pharmatech A/S.
As of October 12, 1995, Bjarne Tommy Pedersen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of October 12, 1995, Bente Hornbech Grubbe has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 1, 1995, Keld Pedersen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 1, 1995, Richardt Sonnichsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 1, 1995, Bente Hornbech Grubbe has left the board of directors of Novo Nordisk Pharmatech A/S.
As of February 4, 1994, Kurt Anker Nielsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of February 4, 1994, Jørgen Grønlund Nielsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of February 4, 1994, Bent Stig Vase has left the board of directors of Novo Nordisk Pharmatech A/S.
As of February 4, 1994, Kjell Hans Bakke has left the board of directors of Novo Nordisk Pharmatech A/S.
As of September 8, 1993, Hans Georg Boye Nielsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of September 8, 1993, Jonna Annelise Skovager has left the board of directors of Novo Nordisk Pharmatech A/S.
On August 29, 1992, the company changed its name from FERROSAN FINE CHEMICALS A/S to FEF CHEMICALS A/S.
On June 1, 1990, the company changed its name from A/S PSE NR. 3369 to FERROSAN FINE CHEMICALS A/S.
As of May 31, 1990, Erik Tronborg Andersen has stepped down as auditor of Novo Nordisk Pharmatech A/S.
As of May 31, 1990, Ulf Svejgaard Poulsen has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 31, 1990, Susanne Saul Stakemann has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 31, 1990, Per Emil Hasselbalch Stakemann has left the board of directors of Novo Nordisk Pharmatech A/S.
As of May 31, 1990, Per Emil Hasselbalch Stakemann has stepped down as director of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Erik Tronborg Andersen has been appointed auditor of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, A/S PSE NR. 4820 has been appointed auditor of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Kurt Anker Nielsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Bjarne Mølgaard Knudsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Bjarne Mølgaard Knudsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Jørgen Grønlund Nielsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Ulf Svejgaard Poulsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Bjarne Tommy Pedersen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Bent Stig Vase has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Susanne Saul Stakemann has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Keld Pedersen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Hans Georg Boye Nielsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Hans Georg Boye Nielsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Sonnich Jacob Fryland has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Per Emil Hasselbalch Stakemann has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Per Andersen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Kjell Hans Bakke has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Jonna Annelise Skovager has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Richardt Sonnichsen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Bente Hornbech Grubbe has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Bente Hornbech Grubbe has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Jens Hartvig Jørgensen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Ole Regnar Hansen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Birgit Mindegaard has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Kim Antero Bjørnholt has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Jesper Frank Morthensen has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Bente Margrethe Skov Schultz has joined the board of directors of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Per Emil Hasselbalch Stakemann is registered as director of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, Preben Engelund Poulsen is registered as director of Novo Nordisk Pharmatech A/S.
As of July 1, 1989, NOVO NORDISK A/S is registered as an owner of Novo Nordisk Pharmatech A/S with an ownership share of 100%.
Novo Nordisk Pharmatech A/S was founded on July 1, 1989.
At Copenhagen Wine, we are deeply committed to wine and love to share our passion with you. You are invited into our world of wine, where each bottle comes with a story, and where you will find carefully selected wines from producers with whom we have an in-depth knowledge and a close relationship. We ensure you the best experiences in the beautiful world of wine.
Selskabets formål er at drive virksomhed med handel og service, samt enhver i forbindelse hermed stående virksomhed.
Companies in the same industry and area
